Anne Shinkwin
Directeur/Bestuurslid bij Multiple Sclerosis Society
Profiel
Anne Shinkwin currently works as a trustee for the Multiple Sclerosis Society.
Actieve functies van Anne Shinkwin
| Bedrijven | Functie | Begin |
|---|---|---|
Multiple Sclerosis Society
 Multiple Sclerosis Society Miscellaneous Commercial ServicesCommercial Services The Multiple Sclerosis Society is an organization that aims to find treatments for everyone affected by multiple sclerosis. The non-profit company is based in London, UK. The British company offers award-winning publications, factsheets, and booklets through their online shop. The society conducts surveys to shape the future direction of MS research, with the latest survey held in 2022 with over 6,500 participants. The company's current focus is on the STARMS trial, which compares HSCT with other highly effective treatments for relapsing MS. The treatment involves using chemotherapy to remove harmful immune cells and regrow the immune system using the patient's own stem cells. Nick Moberly has been the CEO of the company since 2019. | Directeur/Bestuurslid | - |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Bedrijven in privébezit | 1 |
|---|---|
Multiple Sclerosis Society
Multiple Sclerosis Society Miscellaneous Commercial ServicesCommercial Services The Multiple Sclerosis Society is an organization that aims to find treatments for everyone affected by multiple sclerosis. The non-profit company is based in London, UK. The British company offers award-winning publications, factsheets, and booklets through their online shop. The society conducts surveys to shape the future direction of MS research, with the latest survey held in 2022 with over 6,500 participants. The company's current focus is on the STARMS trial, which compares HSCT with other highly effective treatments for relapsing MS. The treatment involves using chemotherapy to remove harmful immune cells and regrow the immune system using the patient's own stem cells. Nick Moberly has been the CEO of the company since 2019. | Commercial Services |
